BioSpace News Archive

The global Point-of-Care Glucose Testing market size is expected to be worth around US$ 6,217.90 million by 2030 from valued at US$ 10.05 million in 2020 and is anticipated to grow at a CAGR of 3.85% from 2021 to 2030.

RemSleep Holdings Inc. announces the company has formally retained a new Senior Director for Regulatory Compliance and Regulatory submissions to gain FDA clearance to market the company’s medical device respiratory products.

Next Generation Immune Checkpoint Inhibitor TIM 3 Antibodies Will Be More Prominently Used As Combinational Cancer Therapy Says Kuick Research.

Veltex Corporation (OTCQB:VLXC) (“Veltex”), a Health and Wellness Acquisition Firm, is pleased to announce its successful uplisting from the OTC Pink Market to the OTCQB® Venture Market (the “OTCQB”) effective for trading July 25, 2022 at the open.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the closing of an underwritten public offering of 13,225,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.

Stevanato Group S.p.A. announced that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. on Thursday, August 4, 2022 to discuss results.

Ligand Pharmaceuticals Incorporated will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), is pleased to announce the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors.